Pharmaceutics International Inc, a United States-based Contract Development and Manufacturing Organisation, has named Kurt R Nielsen, PhD as its new president and CEO, effective immediately, it was reported yesterday.
Dr Nielsen is a pharmaceutical executive with more than 20 years of diverse experience, most recently as the president of Lupin Somerset, responsible for all of its generic and branded products. Prior to Lupin, he held the post of vice president, US Development, Portfolio and Launch Management at Sandoz Inc, where he was accountable for the US development of generic, OTC and specialty brand products. Dr Nielsen has also held positions at Catalent, where he was senior vice president of R&D and chief technology officer, and URL Pharma where he was the executive vice president, Pharmaceuticals.
Dr Abidi, the company's founder and executive chairman of the board of directors, said, 'The appointment of Dr Nielsen to the position of president and CEO reflects a further commitment to growth, building upon Pii's legacy of success, his diverse experiences, proven leadership and industry insights will be instrumental in achieving our strategic objectives.'
Perrigo awarded US FDA's final approval for AB Rated generic Zovirax Cream 5%
Mylan wins US FDA approval for Wixela Inhub for treating asthma & COPD patients
The US Food and Drug Administration approves first generic Advair Diskus for COPD
FDA Approves Dr. Reddy's Tosymra 10 mg, in the US Market
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the US Market
Amerigen awarded US FDA's approval for generic mixed amphetamine salts, extended-release capsules
Amneal wins US FDA approval for Rivastigmine Transdermal System
Premier Expands Effort to Supply Shortage Generic Drugs
Ferring Pharmaceuticals Adds Two Products to its Reproductive Health Portfolio in the US
China's Bio-Thera Solutions Partners with Cipla to Market Key Cancer Biosimilar
EpicGenetics Moves into New Facility, Expanding Capacity by 4X